Vanguard Australian Shares Index ETF

VAS

VAS.AX was created on 2009-05-04 by Vanguard. The fund's investment portfolio concentrates primarily on total market equity. Vanguard Australian Shares Index ETF seeks to track the return of the S&P/ASX 300 Index before taking into account fees, expenses and tax.

Clinuvel Pharmaceuticals Limited

CUV

Clinuvel Pharmaceuticals Ltd. operates as a biopharmaceutical company. The company is headquartered in Melbourne, Victoria. The company went IPO on 2001-02-13. The firm is focused on developing and commercializing treatments for patients with genetic, metabolic, systemic, and life-threatening, acute disorders, as well as healthcare solutions for specialized populations. Its lead therapy, SCENESSE (afamelanotide 16mg), is approved for commercial distribution in Europe, the USA, Israel, and Australia as the first systemic photoprotective drug for the prevention of phototoxicity (anaphylactoid reactions and burns) in adult patients with erythropoietic protoporphyria (EPP). The Company’s pharmaceuticals product development includes PRENUMBRA and NEURACTHEL. Its PhotoCosmetics product development includes CYACELLE and DNA Repair Assist and Melanogenesis. PRENUMBRA is a formulation of afamelanotide designed to provide a flexible dose in identified patient groups. NEURACTHEL is a novel formulation of the melanocortin adrenocorticotropic hormone (ACTH).

Vanguard MSCI Index International Shares ETF

VGS

VGS.AX was created on 2014-11-18 by Vanguard. The fund's investment portfolio concentrates primarily on total market equity. Vanguard MSCI International Shares Index ETF seeks to track the return of the MSCI World ex-Australia Index (with net dividends reinvested) in Australian dollars before taking into account fees, expenses and tax.

Global X Battery Tech & Lithium ETF

ACDC

ACDC.AX was created on 2018-08-30 by Global X. The fund's investment portfolio concentrates primarily on theme equity. The ETF currently has 403.24m in AUM and 34 holdings. The Fund aims to provide investors with a return that (before fees and expenses) tracks the performance of the Solactive Battery ValueChain Index (the Index).

Clearvue Technologies Limited

CPV

ClearVue Technologies Ltd. engages in the provision of photovoltaic and nano-technology to produce clear glass that generates electricity. The company is headquartered in Perth, Western Australia. The company went IPO on 2018-05-25. The firm operates in the building integrated photovoltaic (BPIV) sector which involves the integration of solar technology into building surfaces, specifically glass and building facades, to provide renewable energy. Its principal activities include developing a sale and leads pipeline for the Company’s products, licensing activities to appoint new manufacturers and distributors, as well as research and development activities applied to the Company’s solar glass technology. The company has developed advanced glass technology that aims to preserve glass transparency to maintain building aesthetics whilst generating electricity. Its products include Solar vison glass, Smart Solar Facade, Solar Cladding, Architectural BIPV, and Horticultural solar glass. Its solar glass can be utilized in windows, skylights, greenhouses, and facades, providing energy to power autonomous features or to feed into a grid or battery storage.